You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
InDex Pharmaceuticals - Update on recently announced results of PK-study with cobitolimod
Meet and ask questions to CEO Jenny Sundqvist and CDO Eva Arlander from InDex Pharmaceuticals Tuesday the 28th of March at 3.00 PM.
CEO Jenny Sundqvist will give a recap of the company and its on-going phase III program and CDO Eva Arlander will give an update on the recently announced results of the PK-study with cobitolimod.
InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.
Disclaimer: HC Andersen Capital receives payment from InDex Pharmaceuticals for a DigitalIR/Corporate Visibility agreement./ Claus Thestrup 10.10 AM 22-03-2023.